A Modern Healthcare Collaboration
Labs, patients, and technology must all work together to deliver forward-thinking patient-centered care.
Keeps You Up-to-Date on Federal & State Laws, Regulations, New Legislation, and Court Cases that Affect Your Diagnostic Lab or Pathology Practice
Labs, patients, and technology must all work together to deliver forward-thinking patient-centered care.
As we move further into 2023, COVID-19, add-on, and genetic tests will likely remain targets for federal regulators.
Recent fraud case involving phlebotomy company shows why labs need to pay special attention to Medicare specimen collection and travel allowance rules.
A look at the US end-of-emergency game plan and how it will impact lab compliance.
Sales and marketing operations liability risks and the measures labs should and shouldn’t take to manage those risks.
Even though PAMA has slashed reimbursement rates for many tests, overall Medicare Part B spending on lab tests continues to increase.
At the end of 2022, the agency sent a new warning letter to Empowered for unauthorized distribution of COVID-19 test kits.
Case is a recent example of the trend toward Medicare schemes involving telehealth, cancer genetic testing, and kickbacks.
While the federal spending bill passed at the end of 2022 will have a large impact on clinical labs, it doesn’t include LDTs reform.
Legislation offering permanent relief from both PAMA price cuts and reporting didn’t make it into the federal spending bill passed Dec. 23.
According to a recent CMS report, the sheer volume of out-of-network payment disputes is overwhelming the system.